英飛特(300582.SZ):重大資產購買涉及的14個國家的非股權資產交割工作已完成
格隆匯7月4日丨英飛特(300582.SZ)披露重大資產購買事項的實施進展,截至公吿披露日,公司已召開第三屆董事會第三十九次會議,審議通過了《關於簽署<股權及資產購買協議之補充協議(三)>的議案》;各方已簽署《股權及資產購買協議之補充協議(三)》以及斯洛伐克、英國、波蘭、希臘、奧地利、捷克、法國、芬蘭、西班牙、葡萄牙、丹麥、保加利亞、瑞典和挪威的LATA(非股權資產轉讓協議)。2023年7月3日,公司與OSRAM GmbH、OSRAM S.p.A.簽署了交割備忘錄,前述十四個國家的非股權資產交割工作已完成。公司正在積極推進其餘非股權資產的交割工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.